ANA975

ANA975 is an orally bioavailable prodrug of isatoribine (ANA245), a small molecule toll-like receptor 7 (TLR7) agonist. Developed by Anadys Pharmaceuticals in collaboration with Novartis, it was primarily investigated for the treatment of chronic hepatitis C virus (HCV) infection. ANA975 is designed to be converted into the active nucleoside analog isatoribine through hydrolysis by esterases and oxidation by aldehyde oxidase. By activating TLR7, a pattern-recognition receptor, the drug triggers the innate immune response, specifically inducing interferon-alpha and other cytokines to inhibit viral replication. Clinical development was discontinued in July 2007 following Phase I trials because toxicology studies indicated that chronic daily dosing was unlikely to provide an adequate therapeutic index for the treatment of HCV.

Other names

5-amino-3-β-D-ribofuranosyl-3H-thiazolo[4,5-d]pyrimidin-2-one derivative